2. Immunology/Inflammation
  3. CD74
  4. Milatuzumab

Milatuzumab  (Synonyms: 米拉组单抗; hLL1; MEDI-115)

目录号: HY-P99731 纯度: 99.39%
COA

摩尔计算器

Milatuzumab (hLL1; MEDI-115) 是一种人源化抗 CD74 单克隆抗体。CD74 是一种完整的膜蛋白，与促进 B 细胞生长和存活有关。Milatuzumab 导致自由基氧的产生和线粒体膜电位的丧失。 Milatuzumaba 还降低 CD20/CD74 聚集体和细胞粘附，从而导致细胞死亡。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

CAS No. : 899796-83-9

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥2800
In-stock
5 mg ￥7200
In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Customer Review

Milatuzumab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].

同型

Human IgG1 kappa
推荐同型对照抗体
种属

Humanized
IC50 & Target

CD74[1]
体外研究
(In Vitro)

Milatuzumaba（5 μg/mL；8-48 小时）增强 MCL 细胞系和原发性患者肿瘤细胞的细胞死亡[1]。
Milatuzumaba（5 μg/mL；0.5-2 h）在 Jeko、Mino 和 SP-53 细胞中介导细胞毒性，部分取决于 ROS 的产生和线粒体跨膜电位的丧失[1]。
Milatuzumaba（5 μg/mL；4 小时）抑制 NF-κB 通路并诱导细胞凋亡，凋亡机制与 caspase 裂解、Bcl-2 家族成员失调或诱导自噬无关[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Milatuzumab 相关抗体:

Western Blot Analysis[1]

Cell Line: Jeko and Mino cells
Concentration: 5 μg/mL
Incubation Time: 4 hours
Result: Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.

Cell Viability Assay[1]

Cell Line: MCL cell lines and primarypatient tumor cells
Concentration: 5 μg/mL
Incubation Time: 8, 24, and 48 hours
Result: Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells.

Immunofluorescence[1]

Cell Line: Jeko, Mino, and SP-53 cells
Concentration: 5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h
Incubation Time: 0.5, 1, 1.5, and 2 hours
Result: Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.
体内研究
(In Vivo)

Milatuzumaba（15 mg/kg/天；腹腔注射；每 3 天一次）显着提高携带 Jeko 癌细胞的雌性 SCID 小鼠的存活率。并且Milatuzumaba与Rituximab (HY-P9913) 在该小鼠模型中具有协同作用[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Jeko mouse model[1]
Dosage: 15 mg/kg/day; with or without 15 mg/kg Rituximab
Administration: Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
Result: Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

米拉组单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
纯度 & 产品资料

纯度: 99.39%

COA (172 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Milatuzumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Milatuzumab899796-83-9hLL1 MEDI-115米拉组单抗hLL 1hLL-1MEDI115MEDI 115MEDI-115CD74HLA-DR-gammaInvariant polypeptide of major histocompatibility complex, class II antigen-associatedInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Milatuzumab
目录号：
HY-P99731
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z